

RESEARCH

Open Access



# Isolation and characterization of *Acinetobacter baumannii* from environmental waters in Dhaka City, Bangladesh

Mohammed Aziz Hossain<sup>1</sup> , Nayara Noor E. Fatima<sup>2</sup> , Jahid H. Tushar<sup>2</sup> , Hasib Mahmud<sup>2</sup> and Fahim Kabir Monjurul Haque<sup>2\*</sup>

## Abstract

*Acinetobacter baumannii*, a gram-negative bacterium commonly associated with nosocomial infections, has been relatively unexplored in the environmental context. The present study was conducted in Dhaka City, Bangladesh, with the primary objective of isolating and characterizing *A. baumannii* in environmental water sources. Surface water samples were collected from various water reservoirs to detect the presence of *A. baumannii*. Isolates were confirmed as *A. baumannii* using culture and PCR. Confirmed isolates were screened for antimicrobial susceptibility, antimicrobial resistance genes, and serum resistance. Results revealed that 32% of the water samples tested positive for *A. baumannii*. In total, 23 *A. baumannii* isolates were obtained. All isolates showed resistance to Cefepime. Varying degrees of resistance to other antibiotics were observed, and 56% showed resistance to the bactericidal effect of serum. This study underscored the remarkable adaptability of *A. baumannii* and its ability to flourish in diverse environmental conditions, highlighting public health concerns of increasing antibiotic resistant bacteria. The study concluded that, given the significance of effective infection control and sanitation and waste management measures, understanding the presence and behavior of *A. baumannii* in the environment is paramount. This study acts as the first report on environmental *A. baumannii* in Bangladesh and further research is warranted to elucidate the underlying mechanisms of antibiotic resistance and their implications for human health.

## Highlights

- Molecular characterization confirmed 23 isolates as *A. baumannii* from 31 unique water sites in Dhaka City.
- Resistance to cefepime was observed in all isolates (100%), with a significant proportion also displaying resistance to ceftazidime (65%) and imipenem (56%).
- 30% of isolates were positive for NDM and OXA-48 genes, the latter being an atypical result.
- A majority of the isolates (56.5%) were resistant to human serum.

**Keywords** Environmental *Acinetobacter baumannii*, Antibiotic resistance, Serum resistant *Acinetobacter baumannii*, Antibiotic Resistant *Acinetobacter baumannii*

\*Correspondence:

Fahim Kabir Monjurul Haque  
fahim.haque@bracu.ac.bd

Full list of author information is available at the end of the article



© The Author(s) 2025. **Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

## Introduction

*Acinetobacter baumannii* (*A. baumannii*) is a gram-negative bacterium that causes nosocomial infections [1]. *A. baumannii* infections can range from mild, self-limiting infections such as urinary tract infections (UTIs) to severe infections such as pneumonia, meningitis, and sepsis [2]. This bacterium's potential severeness led the World Health Organization (WHO) to classify it as a priority pathogen for research and development of new antibiotics.

Globally, *A. baumannii* has been studied extensively in hospital settings. Infection with *A. baumannii* has increased Intensive Care Unit (ICU) admissions and hospital stays in the past decades [3, 4]. In India, a tertiary hospital found a high prevalence of *A. baumannii* infections common in the ICU with more extended stays and higher mortality [5]. In Wuhan, China, a retrospective study of hospitalized COVID-19 patients found that nearly half died from secondary bacterial infections, 36% of which were caused by *A. baumannii* [6].

The clinical significance of *A. baumannii* can be attributed to several factors, including antibiotic resistance. This bacterium tends to acquire resistance to multiple classes of antimicrobials [7]. Multi-drug-resistant (MDR) and extensively drug-resistant (XDR) is defined as resistance to three or more antimicrobial classes and resistance to all but 1 or 2 classes of antimicrobial agents [8]. The ability of *A. baumannii* to acquire resistance to antibiotics is due to a combination of factors, including its ability to acquire plasmids with resistance genes and produce efflux pumps that pump out antibiotics from the bacterial cell. All *A. baumannii* isolates possess an efflux system but resistance develops in case of hyperexpression [9]. In addition to the inherent resistance that *A. baumannii* possesses, the emergence of rapidly acquired resistance markers contributes to the emergence of a pan-resistant pathogen [10].

Resistance to human serum attributes *A. baumannii* to bacteremia with a high mortality rate [11]. Studies have shown polysaccharide capsules protect *Acinetobacter* species from unsettled environmental conditions and phagocytosis, complement-mediated lysis, or antimicrobial activity [12–15]. According to another research, *A. baumannii* binds Factor H (FH) via the outer membrane porin OmpA, contributing to its serum resistance [16]. These contribute to a higher degree of pathogenicity.

In previous studies, the environmental reservoirs for *A. baumannii* outside hospitals were unclear [17], with a lack of reports on environmental *A. baumannii* in Bangladesh, and its presence outside the hospital was considered atypical. Studies have reported that *A. baumannii* was isolated from soil contaminated with hydrocarbons in countries with different climates and conditions [18]

[19]. *A. baumannii* has also been isolated from vegetables, meat, unprocessed milk, and cheese obtained from supermarkets, greengrocers, and private gardens [20, 21]. As a result, this opens the possibility of studying *A. baumannii* in the environment. Some studies have found that *A. baumannii* can leach from hospital wastewater to hospital-adjacent community waters, and can survive for prolonged periods [22].

Previous research has also concluded that the presence of *A. baumannii* beyond hospital environments suggests multiple transmission routes, such as wastewater discharge and contamination, human and animal reservoirs, agricultural runoffs, and contact with contaminated food sources, all of which are likely sources of contamination in a densely populated city like Dhaka. [23]

Despite being a global health concern, in Bangladesh, *A. baumannii* studies are almost exclusively focused on nosocomial infections and hospital environments. Little to no effort has been given to study this organism in its natural habitat, which is concerning given the ease of transmission through frequently used waterbodies in the densely populated capital city of Bangladesh. Thus,

The purpose of this study is to isolate *A. baumannii* from water reservoirs, particularly lakes and rivers in Dhaka City. The source of *A. baumannii* is not clinical; therefore, this work also aims to assess its antibiotic susceptibility to clinically relevant antibiotics and determine whether it possesses pathogenic determinants to provide insight regarding this organism's heterogeneity.

## Method

### Sample collection, processing, and isolation of bacteria

Water samples from 31 unique water sites which consist of the major waterbodies of Dhaka City, including lakes, rivers, and ponds were brought to the laboratory in sterile 50 mL falcon conical tubes following FDA guidelines for water samples [24]. All of the aforementioned sites are major hubs of public transport, irrigation, and water from the sites are regularly used for domestic purposes by the residents of Dhaka. 1 mL of the water sample was mixed with sterile 9 mL saline to obtain a ten-fold serial dilution. This process was repeated 5 times, after which they were spread onto Leeds *Acinetobacter* Agar plates. The plates were then incubated at 44 °C for 24 h. Colonies suspected to be *A. baumannii* were selected according to the Leeds *Acinetobacter* Agar Base technical datasheet [25]. These colonies were multiplied in Nutrient Agar for further characterization.

### Molecular characterization of *A. baumannii* isolates

DNA was extracted using a modified boiling method [26]. Briefly, 2–3 bacterial colonies suspected of being *Acinetobacter baumannii* were selected and suspended

into a microcentrifuge (MCT) tube containing 200  $\mu$ L Tris–EDTA (TE) buffer. The tubes were boiled at 100 °C in a water bath for 10 min. Afterward, the tubes were centrifuged at 14,000  $\times$ g for 5 min. Subsequently, the supernatant containing the DNA was collected. Polymerase Chain Reaction (PCR) was used to confirm the *A. baumannii* isolates by targeting two different *A. baumannii*-specific genes, *bla*<sub>OXA-51</sub>, and *16S-23SrDNA*.

PCR was performed based on the identification of the *bla*<sub>OXA-51</sub> gene for *A. baumannii* (primers: OXA-51-F: 5'-TAATGCTTTGATCGGCCTTG-3' and OXA-51-R: 5'-TGGATTGCACTTCATCTTGG-3' [27]. PCR mixtures were made in a 15- $\mu$ L volume comprising 4.9  $\mu$ L Nuclease free water, 7.5  $\mu$ L 2 $\times$  PCR Master Mix (Takara-Bio) 0.3  $\mu$ L of forward and reverse primers (10  $\mu$ M), and 2  $\mu$ L of DNA template. The PCR program was set up in an Applied Biosystem (Thermo Fischer) thermal cycler as follows: 94 °C for 5 min, followed by 30 cycles of 94 °C for 1 min, 55 °C for 1 min, 72 °C for 1 min, and a final extension at 72 °C for 10 min [27]. The expected size for the *bla*<sub>OXA-51</sub> gene is 353 bp. Additionally, PCR was performed by targeting the *16S-23SrDNA* gene (primers: P-Ab-ITSF: 5'-CATTATCACGGTAATTAGTG-3' and PAb-ITSB: 5'-AGAGCACTGTGCACTTAAG-3' [28]. PCR mixtures were prepared similarly to the process discussed above, and the PCR program was set up in an Applied Biosystem (Thermo Fischer) thermal cycler as follows: 94 °C for 6 min, followed by 34 cycles of 95 °C for 50 s, 58 °C for 70 s, 72 °C for 55 s, and a final extension at 72 °C for 10 min [28]. The expected size for the *16S-23SrDNA* gene is 930 bp.

The PCR products were subjected to electrophoresis (110 V, 45 min) in 2% agarose gel in TBE buffer (40 mM Tris, 20 mM boric acid, 1 mM EDTA, pH of 8.0) containing 0.5  $\mu$ g/mL DNA ethidium bromide dye. The gels were examined with ultraviolet illumination and the resulting images were saved and stored. Images were modified using ImageJ [29]. In total, 23 isolates were confirmed to be *A. baumannii* via PCR.

#### Antimicrobial susceptibility testing

Pure cultures of the *A. baumannii* that were confirmed using PCR were used for antibiotic susceptibility tests. The test was carried out using the Kirby-Bauer disc diffusion method in Mueller–Hinton agar (MHA) according to the Clinical Laboratory Standards Institute guidelines [30]. The following antimicrobial discs were used: amikacin 30  $\mu$ g(AK), cefepime 30  $\mu$ g(CPM), ceftazidime 30  $\mu$ g(CAZ), ciprofloxacin 5  $\mu$ g(CIP), doxycycline 30  $\mu$ g(DO), gentamicin 10  $\mu$ g(CN), imipenem 10  $\mu$ g(IMP), levofloxacin 5  $\mu$ g(LE), meropenem 10  $\mu$ g(MRP), piperacillin-tazobactam 100/10  $\mu$ g(TZP), tetracycline 30

$\mu$ g(TE), trimethoprim-sulfamethoxazole 1.25/23.75  $\mu$ g (CoT).

Overnight cultures of *A. baumannii* were used to make a 0.5 McFarland standard suspension before lawning the bacterial suspension onto MHA agar plates [31]. Selected antibiotic discs were placed onto the plates in a sterile manner. The plates were then incubated at 37 °C for 24 h before measuring the zone of inhibition for the antibiotics and the results were interpreted using the interpretive criteria provided by CLSI [30]. We defined multi-drug resistant (MDR) and extensively drug-resistant (XDR) as bacterial resistance to three or more antimicrobial classes and resistance to all but 1 class of antimicrobial agents [8].

#### Antibiotic-resistant genes

Presence of OXA-23, OXA-24, OXA-48, *bla*-GES, *bla*KPC, SPM and NDM were determined using PCR. PCR amplifications were performed in an Applied Biosystem (Thermo Fischer) thermal cycler, and all runs included negative DNA control consisting of Nuclease-free water.

#### Serum resistance assay

Serum resistance assay was performed using a slightly modified version of the described protocol [32]. A single colony grown overnight on Nutrient Agar plates of each isolate was added to 1 mL fresh LB broth and incubated in a shaker incubator at 37 °C for 2 h. The culture was centrifuged at 8,000  $\times$ g for 7 min and the supernatant was removed. The pellet obtained was resuspended with 1 mL of sterile saline. In a sterile 96-well microtiter plate (Corning, USA), 20  $\mu$ L aliquots of the culture-saline mix were treated with 180  $\mu$ L of pooled normal human serum (NHS). A ten-fold serial dilution was performed up to 7 times before 10  $\mu$ L of serum-treated cells was taken from each dilution and plated on Nutrient Agar plates. The initial plating was referred to as 0 h. Afterward, the microtiter plate was incubated at 37 °C for 3 h. This was followed by a ten-fold serial dilution performed up to 7 times before 10  $\mu$ L of serum-bacteria mix was taken from each dilution and plated on Nutrient Agar plates again. Bacterial colonies were enumerated after the Nutrient agar plates had been incubated at 37 °C for 24 h. To assess the serum resistance, the colony-forming units (CFU) were compared from the plates at the beginning (0 h) and end (3 h) of the incubation time, and a paired T test was conducted between the 0-h and 3-h plates. If the CFU count remained the same or increased after 3 h of incubation, it was categorized as resistant, whereas a decrease in the count at the 3-h mark indicated sensitivity. The experiment for serum assay was performed in triplicates.



## Data analysis

Data were transferred to Microsoft Excel spreadsheets (Microsoft Corp., Redmond, WA, USA) for analysis. GraphPad Prism 10 was used for generating graphs. Data obtained in this study are available in Supplementary Table S1.

## Results

### Sampling sites and bacterial identification


The purpose was to determine whether *A. baumannii* is present in environmental water sites. For this, water samples from 31 surface water sites (Fig. 1) were analyzed for the presence of *A. baumannii* which showed pink opaque colonies on Leeds Acinetobacter Agar Based on the PCR amplification of the *bla*<sub>OXA-51</sub> and *16S-23SrDNA* gene (Supplementary Figs. S1 A & B), *A. baumannii* was positive for 10 of the 31 samples, indicating a prevalence rate of 32%. In addition, 23 isolates of *A. baumannii* were obtained from the positive samples. An overview of the sampling location is provided in Supplementary Table S2.

### Antimicrobial susceptibility testing


All the isolates tested were found to be resistant to cefepime (Fig. 2). Varying levels of susceptibility to doxycycline, gentamicin, tetracycline, and amikacin were observed with sensitivities of 60%, 60%, 70%, and almost 90%, respectively. Sixty-five percent (65%) of isolates showed resistance to ceftazidime. When compared, imipenem had a significantly higher resistance of 56% than meropenem (4%). The resistance for ciprofloxacin, and levofloxacin were 52.5% and 47.8% respectively. The highest instance of intermediate resistance was seen with piperacillin-tazobactam, at around 45%, surpassing all other antibiotics tested (Fig. 2).

### Resistance to antibiotic classes, MDR, and XDR distribution

The 13 antibiotics used fall under seven antibiotic classes and the goal was to observe how many of the isolates were resistant to different antibiotic classes. 14 isolates showed resistance to 3 or more antibiotic classes, with the highest levels of resistance being observed in 5 isolates for both 4 and 6 antibiotic classes respectively



**Fig. 1** The sample collection sites pointed on QGIS using GPS coordinates. Blue dots represent sample points that yielded negative results, while the red dots indicate sample points from which *A. baumannii* was isolated




**Fig. 2** Antimicrobial susceptibility (AST) pattern against environmental *A. baumannii* isolates. COT = Trimethoprim-sulfamethoxazole, DO = Doxycycline, TE = Tetracycline, AK = Amikacin, N = Gentamicin, CAZ = Ceftazidime, CPM = Cefepime, CTR = Ceftriaxone, CIP = Ciprofloxacin, LE = Levofloxacin IMP = Imipenem, MRP = Meropenem, TZP = piperacillin-Tazobactam

(Fig. 3a). No isolate was resistant to all 7 classes of antibiotics. Based on the findings in this study, the isolates can be categorized and distributed into multi-drug resistant (MDR) and Extensively Drug-resistant (XDR) based on resistance to antibiotic classes (Fig. 3b, c).

**MAR index**

The multiple antibiotic resistance (MAR) index was calculated as a ratio of resistance to the number of antibiotics by the isolates ('a') to that of the number of antibiotics used('b') [33]. Data show that there is a wide range of



**Fig. 3** **a** Resistance to antibiotic classes by environmental *A. baumannii* isolates. **b, c** Distribution of MDR and XDR of environmental *A. baumannii* isolates

MAR indices among the isolates (Table 1). Notably, none of the isolates had a MAR index of 1.0, which indicates resistance to all 13 antibiotics tested, or 0.9, which means resistance to 12 antibiotics. Similarly, there were no cases of MAR indices at 0.8, which would indicate resistance to 11 or 10 antibiotics. However, there is a trend of MAR indices ranging from 0.1 to 0.8, indicating different

levels of resistance. Approximately 13% of the isolates had MAR indices of 0.8 and 0.7, which implies resistance to 10 and 9 antibiotics, respectively. A prevalence of 9% was observed for MAR indices of 0.6, 0.5, and 0.2, corresponding to resistances against 8, 7, and 3 antibiotics, respectively. In addition, 4% of the isolates had a MAR index of 0.4, indicating resistance to 5 antibiotics, while 9% showed MAR indices of 0.3 (4 antibiotics) and 0.2 (2 antibiotics).

**Table 1** Multiple Antibiotic Resistance (MAR) Index of each *A. baumannii* isolate obtained from the environment

No of Antibiotics Resistant to (a)	No. Antibiotics tested (b)	MAR index (a/b)	Frequency of MAR isolates (n = 23)	Percentage of MAR
13	13	1.0	0	0%
12	13	0.9	0	0%
11	13	0.8	0	0%
10	13	0.8	3	13%
9	13	0.7	3	13%
8	13	0.6	1	4%
7	13	0.5	3	13%
6	13	0.5	2	9%
5	13	0.4	1	4%
4	13	0.3	2	9%
3	13	0.2	2	9%
2	13	0.2	1	4%
1	13	0.1	5	22%


### AMR Genes

Based on the AST findings, our goal was to determine if the isolates were carrying any known AMR genes for *A. baumannii*. The distribution of OXA-23, OXA-24, blaGES, blaKPC, SPM, and NDM genes is shown (Fig. 4). PCR was positive for NDM (Supplementary Fig. S3) and OXA-48 (Supplementary Fig. S4). Notably, 7 out of 23 isolates (30%) were positive for NDM and OXA-48.


### Serum resistance assay

The final objective was to observe if the isolates were capable of surviving against serum treatment. The 23 isolates were tested against human pooled serum (shown in Fig. 5). Findings reveal that most of the isolates were resistant to human serum at a rate of 56.5% (13 out of 23), which was evident by the increase in CFU/ml in the 3 h plates compared to the 0 h plates, with GL-2 showing the highest increase in CFU/ml. The rest of the isolates

**AMR Gene distribution in environmental *A. baumannii* isolates (n=23)**



**Fig. 4** Percentage frequency distribution of AMR



**Fig. 5** Serum Resistance Assay against environmental *A. baumannii* isolates with *p* values. The bar chart is plotted against mean values with Standard Deviation of the triplicates

(10 out of 23) were serum-sensitive with 6 isolates showing almost no growth after 3 h.

## Discussion

*Acinetobacter baumannii* has historically been widely associated with clinical settings. To that end, *A. baumannii* has been investigated in hospitals and among patients

in Bangladesh [34, 35]. Researchers have previously isolated SPM and OXA-23 carrying *A. baumannii* in urbanized rivers in Southeastern Brazil and Paris, fortifying the capacity of rivers as a reservoir for multi-drug resistant bacteria [36–38]. In Bangladesh however, *A. baumannii*'s existence and diversity in environmental water sources remain largely unexplored. To address this knowledge



gap, surface water samples from various water reservoirs were collected between December 2021 and October 2022 in Dhaka City, Bangladesh. Sampling sites were selected randomly. To the best of our knowledge, this report represents the first identification of *A. baumannii* in environmental water sources exclusive to Bangladesh. 32% of the water samples tested positive for *A. baumannii*, highlighting the potential role of environmental water sources as a vehicle for the spread of *A. baumannii*.

The presence of multi-drug-resistant *A. baumannii* through environmental water sources should be a concern for public health because antibiotic resistance makes it difficult to treat infections. This study found varying degrees of antibiotic resistance by *A. baumannii* isolates. Previous studies conducted in Bangladesh and Romania on clinical *A. baumannii* isolates reported resistance rates to Cefepime at 95% and 93%, respectively [34, 35]. In this study, we noted a 100% resistance to cefepime, although this higher percentage is likely influenced by a smaller sample size ( $n = 23$ ). Previous studies conducted in Bangladesh with a similar sample size of 20 clinical ESBL-producing *A. baumannii* isolates have reported high levels of resistance to Imipenem and Ceftriaxone (81.81% for both) [39], with one study having 22 isolates reporting 100% resistance to Ciprofloxacin [40]. Although the isolates in this study did not show such high levels of resistance to the aforementioned antibiotics, more than 50% of the isolates were resistant to Imipenem, and Ceftriaxone had the second-largest resistance rate. None of the studies had isolates with 100% resistance to Cefepime, and there have been no reports of XDR *A. baumannii* in clinical settings, but the resistance could be attributed to ESBL production, and needs to be investigated further. The presence of MDR and XDR *A. baumannii* in surface water suggests increased antimicrobial resistance compared to previous studies, and will likely pose a significant challenge to infection control in the future. Recent research underscores the rapid spread of antimicrobial resistance (AMR) genes, such as *bla*<sub>NDM</sub>, *bla*<sub>KPC</sub>, and *mcr*, among pathogens like *A. baumannii*, *Klebsiella pneumoniae*, and *Escherichia coli*, facilitated by plasmids and transposons. If more comprehensive research necessitates future studies, the limited sample number may be addressed by expanding the sampling sites to Dhaka-adjacent waterbodies, and conducting more advanced molecular screening of retrieved isolates.

The MAR index provides a quantitative measure of resistance, and is a simple and effective tool in communicating resistance, to help clinicians take appropriate drug therapy measures. Incorporating MAR indices in antibiotic stewardship and monitoring results in detailed surveillance, allowing doctors to provide better treatment options [41], which, in Bangladesh, could be used

to designed effective public health measures. The proportion of MAR indices greater than 0.2 was 65% (15), while those with MAR indices of 0.2 or less were 35% (8). These results suggest that a significant portion of our isolates likely originated from an environment where multiple antibiotics were frequently employed before eventually reaching the sampling sites, suggesting that the AMR genes are mobile. This finding is alarming as antibiotic-resistant bacteria can potentially be transferred from the environment to humans who come into contact with these water bodies, posing significant health threats. Due to the limited number of isolates obtained from sampling points, we did not calculate a MAR index for these sites. In the future, it will be taken into consideration should a comprehensive study become necessary.

Carbapenem resistance in *Acinetobacter* species is caused by the production of OXA-type carbapenemases and Metallo-beta lactamase (MBL) [42]. While Carbapenemase such as *bla*<sub>OXA-51</sub> is intrinsic to *Acinetobacter baumannii*, the other carbapenemase and MBL genes such as OXA-48 and NDM are of plasmid origin [43, 44]. All 23 *A. baumannii* isolates were positive for the *bla*<sub>OXA-51</sub> gene which was the basis for determining *A. baumannii*. 7 (30%) of the isolates were positive for NDM and OXA 48, which is an unusual finding, as OXA 48 genes are typical in Enterobacterales, not *A. baumannii*. Previously, NDM positive *A. baumannii* had been isolated from clinical samples in Bangladesh [39], but there have been no reports of NDM carrying *A. baumannii* in the environment, alluding to possible transfer of antibiotic-resistant genes through horizontal gene transfer. Of 13 isolates that showed resistance against imipenem, only 5 of them tested positive for the NDM gene, which suggests unscreened genes could be attributed to imipenem resistance. Only 3 (13%) isolates harbored both NDM and OXA 48 gene where 2 of them were categorized as XDR (one showed meropenem resistance, the other showed intermediate zone), and the remaining one was denoted as MDR. Conclusive results for other AMR genes were not obtained, as the established protocols for PCR resulted in non-specific bands for those genes, which acts as a limitation of this study and may be investigated further should more comprehensive reporting be deemed necessary.

Resistance to bactericidal effects of serum is an important virulence determinant by a bacterium [16]. Although numerous studies have explored serum resistance in clinical *A. baumannii*, we found no pertinent data concerning environmental isolates. The majority of *A. baumannii* isolates (56.5%) in this study were resistant to human serum, with a few being susceptible to the efficacy of serum. While serum resistance is expected in clinical strains due to their origin, it is difficult to ascertain



whether the serum-resistant isolates found in this study are of clinical origin or naturally developed.

Serum resistance accounts for multiple health-related complications in humans, resulting in bacteremia with a high mortality rate. Serum-resistant *A. baumannii* is thought to survive better in vivo and can cause systematic infections, as a result of evading the bacteriocidal effects of human serum [11, 16]. As a result, *A. baumannii* has been designated as a “red alert” human pathogen, which may cause severe infections, given that serum-resistant *A. baumannii* isolated from clinical settings have been found to be ESBL-producing [2]. The water bodies that surround Dhaka City are readily accessible to the general populace, facilitating transport, tourism, and even providing water for domestic purposes for Dhaka citizens. Serum resistance in environmental isolates is highly unlikely and needs to be investigated further.

## Conclusion

This study establishes the MDR and serum-resistant patterns of *A. baumannii* isolated from the major waterbodies of Dhaka City, acting as the first report of antibiotic-resistant *A. baumannii* in Bangladesh. Based on the results presented in this study, *A. baumannii* isolates display varying levels of antibiotic resistance. Resistance to cefepime was observed in all isolates (100%), with a significant proportion also displaying resistance to ceftazidime (65%) and imipenem (56%). Additionally, 30% of isolates were positive for NDM and OXA-48 genes, the latter being an atypical result. The environmental origin of the samples indicates that there is the possibility that mobile AMR genes may have been passed to the environmental isolates. The prevalence of multidrug-resistant strains was also observed, with some isolates showing resistance to three or more antibiotic classes. The MAR indices also indicate a moderate level of resistance to multiple antibiotics. This study also found that serum resistance varied among isolates, with 56.6% being resistant to serum. These findings suggest that *A. baumannii* is a highly adaptive pathogen with a wide range of responses to various conditions. Given the limited number of isolates this research worked with, further investigations using whole genome sequencing (WGS) are warranted to conclude whether the origin of these isolates is clinical or not, and investigate the transmission routes of antibiotic and serum-resistant *A. baumannii* to design comprehensive response measures. Future studies should take these considerations in mind and include a larger sample size, analyze additional antibiotic resistance genes, and conduct more comprehensive MAR indexing for sampling sites.

## Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12866-025-04029-w>.

Supplementary Material 1.

## Acknowledgements

The team would like to thank the BRAC University Life Science Laboratory lab officers and staff for their invaluable assistance and unwavering support throughout this study. The team acknowledges that their contributions and dedication have been crucial to the success of this project.

## Authors' contributions

MAH and FKMH conceptualized and designed the manuscript. MAH, JHT and HM conducted the material preparation, laboratory experiments, and data collection and analysis. MAH, NNEF and FKMH wrote the main manuscript. All authors reviewed the manuscript.

## Funding

No funds, grants, or other support was received.

## Data availability

The datasets generated in this study have been included in the study. Raw data are available from the corresponding author upon reasonable request.

## Declarations

### Ethics approval and consent to participate

Not applicable.

### Consent for publication

Not applicable.

### Competing interests

The authors declare no competing interests.

### Author details

<sup>1</sup>Biotechnology program, Department of Mathematics and Natural Sciences, BRAC University, Kha-224 Pragati Sarani, Merul Badda, Dhaka 1212, Bangladesh. <sup>2</sup>Microbiology Program, Department of Mathematics and Natural Sciences, BRAC University, Kha-224 Pragati Sarani, Merul Badda, Dhaka 1212, Bangladesh.

Received: 3 March 2025 Accepted: 7 May 2025

Published online: 22 May 2025

## References

1. Sisakhtpour B, Mirzaei A, Karbasizadeh V, Hosseini N, Shabani M, Moghim S. The characteristic and potential therapeutic effect of isolated multidrug-resistant *Acinetobacter baumannii* lytic phage. *Ann Clin Microbiol Antimicrob*. 2022;21(1):1–11. <https://doi.org/10.1186/s12941-022-00492-9>.
2. Howard A, O'Donoghue M, Feeney A, Sleator RD. *Acinetobacter baumannii* An emerging opportunistic pathogen. *Virulence*. 2012;3(3):5. <https://doi.org/10.4161/viru.19700>.
3. Fournier PE, Richet H. The epidemiology and control of *Acinetobacter baumannii* in health care facilities. *Clin Infect Dis*. 2006;42(5):692–9. <https://doi.org/10.1086/500202>.
4. Playford EG, Craig JC, Iredell JR. Carbapenem-resistant *Acinetobacter baumannii* in intensive care unit patients: risk factors for acquisition, infection and their consequences. *J Hosp Infect*. 2007;65(3):204–11. <https://doi.org/10.1016/j.jhin.2006.11.010>.
5. Mathai AS, Oberoi A, Madhavan S, Kaur P. *Acinetobacter* infections in a tertiary level intensive care unit in northern India: Epidemiology, clinical profiles and outcomes. *J Infect Public Health*. 2012;5(2):145–52. <https://doi.org/10.1016/j.jiph.2011.12.002>.

6. Karnoukh KI, Drozdov VN, Shikh EV, Zhilina SV, Lazareva NB. Etiology and Antimicrobial Resistance of Secondary Bacterial Infections in Patients Hospitalized with COVID-19: A Retrospective Analysis. *Vestnik Rossijskoi Akademii Meditsinskikh Nauk*. 2022;77(1):25–32. <https://doi.org/10.15690/vramn1552>.
7. Adams-Haduch JM, Paterson DL, Sidjabat HE, Pascual AW, Potoski BA, Muto CA, Harrison LH, Doi Y. Genetic basis of multidrug resistance in *Acinetobacter baumannii* clinical isolates at a tertiary medical center in Pennsylvania. *Antimicrob Agents Chemother*. 2008;52(11):3837–43. <https://doi.org/10.1128/AAC.00570-08>.
8. Falagas ME, Karageorgopoulos DE. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among gram-negative bacilli: Need for international harmonization in terminology. *Clin Infect Dis*. 2008;46(7):1121–2. <https://doi.org/10.1086/528867>.
9. Antunes LCS, Visca P, Towner KJ. *Acinetobacter baumannii*: Evolution of a global pathogen. *Pathogens and Disease*. 2014;71(3):292–301. <https://doi.org/10.1111/2049-632X.12125>.
10. Siegel RE. Emerging gram-negative antibiotic resistance: Daunting challenges, declining sensitivities, and dire consequences. *Respir Care*. 2009;53(4):471–9.
11. King LB, Swiatlo E, Swiatlo A, McDaniel LS. Serum resistance and biofilm formation in clinical isolates of *Acinetobacter baumannii*. *FEMS Immunol Med Microbiol*. 2009;55(3):414–21. <https://doi.org/10.1111/j.1574-695X.2009.00538.x>.
12. Geisinger E, Isberg RR. Antibiotic Modulation of Capsular Exopolysaccharide and Virulence in *Acinetobacter baumannii*. *PLoS Pathog*. 2015;11(2):1–28. <https://doi.org/10.1371/journal.ppat.1004691>.
13. Monem S, Furmanek-Blaszk B, Łupkowska A, Kuczyńska-Wisnik D, Stojowska-Swędryńska K, Laskowska E. Mechanisms protecting *acinetobacter baumannii* against multiple stresses triggered by the host immune response, antibiotics, and outside host environment. *Int J Mol Sci*. 2020;21(15):1–30. <https://doi.org/10.3390/ijms21155498>.
14. Russo TA, Luke NR, Beanan JM, Olson R, Sauberman SL, MacDonald U, Schultz LW, Umland TC, Campagnari AA. The K1 capsular polysaccharide of *Acinetobacter baumannii* strain 307–0294 is a major virulence factor. *Infect Immun*. 2010;78(9):3993–4000. <https://doi.org/10.1128/IAI.00366-10>.
15. Singh JK, Adams FG, Brown MH. Diversity and function of capsular polysaccharide in *Acinetobacter baumannii*. *Frontiers in Microbiology*. 2019;10(JAN):1–8. <https://doi.org/10.3389/fmicb.2018.03301>.
16. Kim SW, Choi CH, Moon DC, Jin JS, Lee JH, Shin JH, Kim JM, Lee YC, Seol SY, Cho DT, Lee JC. Serum resistance of *Acinetobacter baumannii* through the binding of factor H to outer membrane proteins. *FEMS Microbiol Lett*. 2009;301(2):224–31. <https://doi.org/10.1111/j.1574-6968.2009.01820.x>.
17. Peleg AY, Seifert H, Paterson DL. *Acinetobacter baumannii*: Emergence of a successful pathogen. *Clin Microbiol Rev*. 2008;21(3):538–82. <https://doi.org/10.1128/CMR.00058-07>.
18. Bordenave S, Goñi-Urriza MS, Caumette P, Duran R. Effects of heavy fuel oil on the bacterial community structure of a pristine microbial mat. *Appl Environ Microbiol*. 2007;73(19):6089–97. <https://doi.org/10.1128/AEM.01352-07>.
19. Sarma PM, Bhattacharya D, Krishnan S, Lal B. Assessment of intra-species diversity among strains of *Acinetobacter baumannii* isolated from sites contaminated with petroleum hydrocarbons. *Can J Microbiol*. 2004;50(6):405–14. <https://doi.org/10.1139/w04-018>.
20. Berlau J, Aucken HM, Houang E, Pitt TL. Isolation of *Acinetobacter* spp including *A. baumannii* from vegetables: Implications for hospital-acquired infections. *J Hospital Infect*. 1999;42(3):201–4. <https://doi.org/10.1053/jhin.1999.0602>.
21. Gennari M, Lombardi P. Comparative Characterization of *Acinetobacter* Strains Isolated from Different Foods and Clinical Sources. *Zentralblatt Fur Bakteriologie*. 1993;279(4):553–64. [https://doi.org/10.1016/S0934-8840\(11\)80428-7](https://doi.org/10.1016/S0934-8840(11)80428-7).
22. Hrenovic J, Durn G, Goic-Barisic I, Kovacic A. (2014). Occurrence of an environmental *Acinetobacter baumannii* strain similar to a clinical isolate in paleosol from Croatia. *Applied and environmental microbiology*. 80(9):2860–6. <https://doi.org/10.1128/AEM.00312-14>.
23. Ahuatzin-Flores OE, Torres E, Chávez-Bravo E. *Acinetobacter baumannii*, a multidrug-resistant opportunistic pathogen in new habitats: a systematic review. *Microorganisms*. 2024; 12(4):644. <https://doi.org/10.3390/microorganisms12040644>.
24. U.S. Food and Drug Administration. Chapter 4 - Sampling. In: *Investigations Operations Manual*. Rev. 08. U.S. Department of Health and Human Services. 2022. <https://www.fda.gov/media/75243/download>. Accessed 16 May 2025.
25. Hardy Diagnostics. *Leeds Acinetobacter Medium: Instructions for Use*. Hardy Diagnostics website. <https://hardydiagnostics.com/media/assets/product/documents/LeedsAcinetobacterMedium.pdf>. Published 2023. Accessed 16 May 2025.
26. Dashti AA, Jadaon MM, Abdulsamad AM, Dashti HM. Heat treatment of bacteria: A simple method of DNA extraction for molecular techniques. *Kuwait Med J*. 2009;41(2):117–22.
27. Falah F, Shokoohizadeh L, Adabi M. Molecular identification and genotyping of *Acinetobacter baumannii* isolated from burn patients by PCR and ERIC-PCR. *Scars, Burns & Healing*. 2019;5:205951311983136. <https://doi.org/10.1177/2059513119831369>.
28. Tavakoli M, Momtaz H, Mohajeri P, Shokoohizadeh L, Tajbakhsh E. Genotyping and distribution of putative virulence factors and antibiotic resistance genes of *Acinetobacter baumannii* strains isolated from raw meat. *Antimicrob Resist Infect Control*. 2018;7(1):1–11. <https://doi.org/10.1186/s13756-018-0405-2>.
29. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. *Nat Methods*. 2012;9(7):671–5. <https://doi.org/10.1038/nmeth.2089>.
30. Clinical and Laboratory Standards Institute. Institute CaLS. Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals CLSI Supplement VET08. Edited by Pennsylvania. CLSI Supplement. 2018;M100(4):282.
31. Simpson CA, Geornaras I, Yoon Y, Scanga JA, Kendall PA, Sofos JN, Biologics D. McFarland Srandard. *J Food Prot*. 2014;71(3):2.
32. Nandanwar N, Janssen T, Kühl M, Ahmed N, Ewers C, Wieler LH. International Journal of Medical Microbiology Extraintestinal pathogenic *Escherichia coli* (ExPEC) of human and avian origin belonging to sequence type complex 95 (STC95) portray indistinguishable virulence features. *Int J Med Microbiol*. 2014;304(7):835–42. <https://doi.org/10.1016/j.ijmm.2014.06.009>.
33. EclinicalMedicine. Antimicrobial resistance: a top ten global public health threat. *EclinicalMedicine*. 2021;41:101221. <https://doi.org/10.1016/j.eclinm.2021.101221>.
34. Babapour E, Haddadi A, Mirnejad R, Angaji SA, Amirmozafari N. Biofilm formation in clinical isolates of nosocomial *Acinetobacter baumannii* and its relationship with multidrug resistance. *Asian Pac J Trop Biomed*. 2016;6(6):528–33. <https://doi.org/10.1016/j.apjtb.2016.04.006>.
35. Gheorghe I, Barbu IC, Surleac M, Sărbu I, Popa LI, Paraschiv S, Feng Y, Lazăr V, Chifiruc MC, Oțelea D, Zhiyong Z. Subtypes, resistance and virulence platforms in extended-drug resistant *Acinetobacter baumannii* Romanian isolates. *Sci Rep*. 2021;11(1):1–12. <https://doi.org/10.1038/s41598-021-92590-5>.
36. Girlich D, Poirel L, Nordmann P. First isolation of the blaOXA-23 carbapenemase gene from an environmental *Acinetobacter baumannii* isolate. *Antimicrob Agents Chemother*. 2010;54(1):578–9. <https://doi.org/10.1128/AAC.00861-09>.
37. Montezzi LF, Campana EH, Corrêa LL, Justo LH, Paschoal RP, Da Silva ILVD, Souza MDCM, Drolshagen M, Picão RC. Occurrence of carbapenemase-producing bacteria in coastal recreational waters. *Int J Antimicrob Agents*. 2015;45(2):174–7. <https://doi.org/10.1016/j.ijantimicag.2014.10.016>.
38. Turano H, Gomes F, Medeiros M, Oliveira S, Fontes LC, Sato MIZ, Lincopan N. Presence of high-risk clones of OXA-23-producing *Acinetobacter baumannii* (ST79) and SPM-1-producing *Pseudomonas aeruginosa* (ST277) in environmental water samples in Brazil. *Diagn Microbiol Infect Dis*. 2016;86(1):80–2. <https://doi.org/10.1016/j.diagmicrobio.2016.06.005>.
39. Hasan MJ, Shamsuzzaman SM. Distribution of adeB and NDM-1 genes in multidrug resistant *Acinetobacter baumannii* isolated from infected wound of patients admitted in a tertiary care hospital in Bangladesh. *Malays J Pathol*. 2017;39(3):277–83.
40. Farzana R, Swedberg G, Giske CG, Hasan B. Molecular and genetic characterization of emerging carbapenemase-producing *Acinetobacter baumannii* strains from patients and hospital environments in Bangladesh. *Infection Prevention in Practice*. 2022;4(2):100215. <https://doi.org/10.1016/j.infpip.2022.100215>.

41. Woh PY, Yeung MPS, Goggins WB. Multiple antibiotic resistance index (MARI) of human-isolated *Salmonella* species: a practical bacterial antibiotic surveillance tool. *J Antimicrob Chemother*. 2023;78(5):1295–9. <https://doi.org/10.1093/jac/dkad092>.
42. Thomson JM, Bonomo RA. The threat of antibiotic resistance in Gram-negative pathogenic bacteria:  $\beta$ -lactams in peril! *Curr Opin Microbiol*. 2005;8(5):518–24. <https://doi.org/10.1016/j.mib.2005.08.014>.
43. Ghazawi A, Sonnevend Á, Bonnin RA, Poirel L, Nordmann P, Hashmeh R, Rizvi TA, Hamadeh B, M., & Pál, T. NDM-2 carbapenemase-producing *Acinetobacter baumannii* in the United Arab Emirates. *Clin Microbiol Infect*. 2012;18(2):2009–11. <https://doi.org/10.1111/j.1469-0691.2011.03726.x>.
44. Turton JF, Woodford N, Glover J, Yarde S, Kaufmann ME, Pitt TL. Identification of *Acinetobacter baumannii* by detection of the bla OXA-51-like carbapenemase gene intrinsic to this species. *J Clin Microbiol*. 2006;44(8):2974–6. <https://doi.org/10.1128/JCM.01021-06>.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.